China Biologic Products Holdings, Inc. (02509): Long-acting dual anti-QX027N obtains two clinical trial implicit approvals.

Wisdom Finance APP news, Quanxing Biotechnology-B (02509) announced that the company's independently developed long-acting dual anti-QX027N injection has obtained the clinical trial implied permit from the Drug Evaluation Center of the National Medical Products Administration (acceptance numbers: CXSL2500757, CXSL2500758), intended for the treatment of asthma and atopic dermatitis. The clinical permit for this candidate drug marks the company's innovative dual anti-matrix in the field of self-immunity and allergic diseases officially entering the clinical stage.